BlackRock
ACTU

BlackRock’s Actuate Therapeutics ACTU Stock Holding History

BlackRock’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.17M Sell
427,153
-4,888
-1% -$20.3K ﹤0.01% 4283
2025
Q4 		$2.64M Buy
432,041
+149,967
+53% +$1.03M ﹤0.01% 4048
2025
Q3 		$1.89M Buy
282,074
+86,622
+44% +$628K ﹤0.01% 4110
2025
Q2 		$1.19M Buy
195,452
+187,854
+2,472% +$1.64M ﹤0.01% 4198
2025
Q1 		$51.4K Sell
7,598
-147
-2% -$1.18K ﹤0.01% 4919
2024
Q4 		$61.7K Buy
+7,745
New +$63.2K ﹤0.01% 4896

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $237M AUM 5.37% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

BlackRock's ACTU Position: Q1 2026 in Review

BlackRock reduced its Actuate Therapeutics (ACTU) stake by 1.1% in Q1 2026, selling an estimated $20.3K and leaving 427,153 shares worth $1.17M. The position accounts for ﹤0.01% of the portfolio, ranked #4283.

BlackRock first reported a position in ACTU in Q4 2024 and has held it in 6 quarters since. The position peaked at $2.64M in Q4 2025. 61 funds tracked by Wall St. Rank hold ACTU as of Q1 2026.

  • BlackRock held 427,153 shares of Actuate Therapeutics worth $1.17M as of Q1 2026.
  • BlackRock sold 4,888 Actuate Therapeutics shares in Q1 2026, an estimated $20.3K.
  • Actuate Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #4283 holding.
  • BlackRock first reported a position in Actuate Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • BlackRock's Actuate Therapeutics position peaked at $2.64M in Q4 2025.
  • 61 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.